Core Viewpoint - The announcement of an exclusive licensing agreement between the company and Boehringer Ingelheim for the dual-specific antibody SIM0709 has positively impacted the company's stock price, reflecting investor confidence in its innovative capabilities in the autoimmune research field [1] Group 1: Licensing Agreement Details - The company’s subsidiary, Jiangsu Xiansheng, signed an exclusive licensing agreement with Boehringer Ingelheim on January 26, 2026, granting Boehringer global exclusive rights to SIM0709 outside Greater China [1] - The agreement includes an upfront payment of €42 million and potential milestone payments up to €1.016 billion based on development progress, regulatory approvals, and commercialization [1] - The company will also receive tiered royalties on net sales outside Greater China [1] Group 2: Product Information - SIM0709 is a long-acting humanized dual-specific antibody developed by the company’s proprietary multi-specific antibody platform [1] - The antibody targets TL1A and IL-23, which are key pathways involved in the onset and progression of inflammatory bowel disease [1] - Preclinical studies have shown that SIM0709 exhibits superior synergistic effects compared to the combination of two single agents in both in vitro and in vivo experiments [1]
港股异动 | 先声药业(02096)高开近6% 与勃林格殷格翰就SIM0709订立独家授权许可协议